Clinical trial
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer
NCT06116786 is registered in ClinicalTrials.gov with Johnson & Johnson Enterprise Innovation Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- November 27, 2023
- Completion date
- November 30, 2027
- Enrollment
- 67 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.